Pratia Prague s.r.o.

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)5 trials
• Psoriasis5 trials
• Osteoarthritis3 trials
• Heart failure2 trials
• Migraine2 trials
• Obesity2 trials
• Psoriatic arthritis2 trials
• Ankylosing spondylitis1 trial
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Stroke1 trial

Phase

• Phase 312 trials
• Phase 27 trials
• Phase 2/31 trial

Status

• Completed11 trials
• Recruiting5 trials
• Active, not recruiting3 trials
• Not yet recruiting1 trial

Lead sponsor

• AbbVie2 trials
• Alumis Inc2 trials
• Novo Nordisk A/S2 trials
• UCB Biopharma SRL2 trials
• Amgen1 trial
• and 11 more

Running trials

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis

  2025-522113-35-00· Phase 2· Triveni Bio Inc.· Source

• Recruiting

  A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

  NCT07216027· Phase 2· Pfizer· Source

• Recruiting

  A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979375· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

  NCT06947993· Phase 2· Novartis Pharmaceuticals· Source

• Not yet recruiting

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy in Patients with Inflammatory Knee Osteoarthritis (KOA).

  2024-514388-24-00· Phase 2· Peptinov· Source

• Active, not recruiting

  Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

  NCT06846541· Phase 3· Alumis Inc· Source

• Active, not recruiting

  Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

  NCT05492578· Phase 2/3· Sanofi· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)2 recruiting
• Heart failure2 recruiting
• Chronic kidney disease1 recruiting
• Obesity1 recruiting
• Osteoarthritis1 recruiting

Closed trials

• Completed

  A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Once Daily Diclofenac Gel AMZ001 3.06% in the Treatment of Pain and Symptoms of Knee Osteoarthritis

  2024-517404-11-00· Phase 3· Amzell B.V.· Source

• Active, not recruiting

  Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

  NCT06806293· Phase 3· AbbVie· Source

• Recruiting

  Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis

  NCT06833749· Phase 2· KeyBioscience AG· Source

• Completed

  A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06602219· Phase 2· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06586112· Phase 3· Alumis Inc· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

  NCT04908202· Phase 3· Bristol-Myers Squibb· Source

• Completed

  A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

  NCT04686136· Phase 3· AbbVie· Source

• Completed

  A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

  NCT04436640· Phase 3· UCB Biopharma SRL· Source

• Completed

  A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

  NCT04009499· Phase 3· UCB Biopharma SRL· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source